Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer

Table 3

First-line drug therapies according to time of diagnosis. Number of patients and overall survival (OS) rates with 95% confidence intervals (CIs) are presented. Seven patients received only chemotherapy and were excluded from data presented in this table.

First-line drug therapy	Time of diagnosis				Total
	2005–2007 (N = 494)		2008–2010 (N = 476)		N = 970
	n (%)	OS (95% CI)	n (%)	OS (95% CI)	n (%)
No medical treatment	260 (52.1)	2.86 (2.22–3.50)	193 (40.4)	3.38 (2.77–4.00)	453 (46.4)
Interferon ± chemotherapy	169 (33.9)	15.3 (12.5–18.1)	17 (3.6)	13.2 (4.74–21.6)	186 (19.0)
TT	65 (13.0)	14.8 (11.9–17.6)	266 (55.6)	20.2 (16.3–24.1)	331 (33.9)